Aquestive Therapeutics Inc (AQST) Quote

Big turn around imminent

Yessir absolutely

In other words you’re confident about this one from the clinical stage drug discovery sector

Not for long

AQST under $5

AQST................................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783

AQST new 52 week hi

AQST...........................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783

I HATE YOU NOW..LOL

AQST new 52 week high

AQST.....................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783

Headed much higher!

AQST..EXIT...MASSIVE PLAY

AQST...BREAKING 4 BUCKS...BEAST

AQST...MONSTER

AQST...MONSTER

AQST monster bio by the master trend

AQST.......................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783

AQST new 52 week high

AQST...NEXT BIO WEEKLY BEAST

Just the beginning

AQST new 52 week high

Offering coming probably soon.

AQST new 52 week high

Initiating this one. Fantastic turnaround by company leadership. Look at the ER from last night and see for yourself.

Toxic slobs is more like it.

On going S-3 shelf placement!

AQST

Aquestive Therapeutics Announces EPIPHAST II Trial Data For AQST-109; Says 'AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen Tmax of 22.5 minutes'
7:05 am ET September 27, 2022 (Benzinga) Print
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
Company hosts conference call at 8:00 am ET on September 27, 2022

https://www.stockscores.com/chart.asp?TickerSymbol=aqst%20&TimeRange=1825&Interval=m&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

me=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

nice

like this

strange POS

strange POS

https://ih.advfn.com/stock-market/NASDAQ/aquestive-therapeutics-AQST/stock-news/88375724/aquestive-therapeutics-reports-positive-initial-to

Quite the hair cut since the delay. I bought in at 4.38 and will buy more if it drops further

AQST - FDA Approval Insight

AQST - Tuesday Rundown, Wednesday Expectations

Parabolic chart for $AQST. PDUFA is on deck.

AQST - Update

AQST - Tuesday Rundown, Wednesday Expectations

AQST - Update

AQST - Thursday Rundown, Friday Expectations

AQST - Update Morning Report

AQST - Tuesday Rundown, Wednesday Expectations

AQST - Morning Report

AQST - Monday Morning Report

AQST - Monday's Plays Which will Short Squeeze

GREAT NEWS!

Aquestive Therapeutics price target lowered to $7 from $10 at Lake Street

Aquestive Therapeutics price target lowered to $7 from $8 at RBC Capital »

Aquestive Therapeutics price target lowered to $13 from $18 at BMO Capital 07:00 AQST BMO Capital analyst Gary Nachman lowered the firm's price target on Aquestive Therapeutics to $13 from $18 but keeps an Outperform rating on the shares. The analyst notes that the CRL for the company's key product Libervant announced by the FDA on Friday is "disappointing, but should be very fixable" in the near term. Nachman adds that Aquestive intends to resubmit the study by the end of the year and expects a PDUFA date for the drug in the first half of 2021.

Read more at:
https://thefly.com/n.php?id=3166457
Aquestive Therapeutics price target lowered to $17 from $23 at JMP

Aquestive Therapeutics price target lowered to $17 from $23 at JMP Securities 06:07 AQST JMP Securities analyst Jason Butler lowered the firm's price target on Aquestive Therapeutics to $17 from $23 but keeps an Outperform rating on the shares. The analyst notes that the company's announcement of an FDA CRL for Libervant announced on Friday is disappointing, but he believes that the path to approval remains "timely and low risk". Butler adds that his probability of approval for the drug remains at 85%, though his model pushes back assumptions for its launch and first sales by one year to 2021.

Read more at:
https://thefly.com/n.php?id=3166393Securities »

https://thefly.com/news.php?symbol=AQST